volibris
glaxosmithkline (ireland) limited - ambrisentan - bluthochdruck, lungen - antihypertensiva, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5. efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease. volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.
isolfan 6 mg/ml konzentrat zur herstellung einer infusionslösung
aspen pharma trading limited (8134622) - busulfan - konzentrat zur herstellung einer infusionslösung - teil 1 - konzentrat zur herstellung einer infusionslösung; busulfan (04529) 6 milligramm
pelmeg
mundipharma corporation (ireland) limited - pegfilgrastim - neutropenie - immunostimulants, - zur verringerung der dauer der neutropenie und die inzidenz von febrile neutropenie durch chemotherapie.
cegfila (previously pegfilgrastim mundipharma)
mundipharma corporation (ireland) limited - pegfilgrastim - neutropenie - immunostimulants, - verkürzung der dauer der neutropenie und dem auftreten von fieberhaften neutropenie bei erwachsenen patienten behandelt mit zytotoxischen chemotherapie bei malignen erkrankungen (mit ausnahme der chronischen myeloischen leukämie und myelodysplastischen syndromen).
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , dreifach-kombinationstherapie) als ergänzung zu diät und bewegung bei patienten, die unzureichend kontrolliert auf ihren maximalen tolerierten dosis von metformin und sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
irinotecan aurobindo 20 mg/ml konzentrat zur herstellung einer infusionslösung
eugia pharma (malta) limited (1010127) - irinotecanhydrochlorid 3 h<2>o - konzentrat zur herstellung einer infusionslösung - teil 1 - konzentrat zur herstellung einer infusionslösung; irinotecanhydrochlorid 3 h<2>o (28859) 20 milligramm
quetiapin accord 300 mg filmtabletten
accord healthcare limited (8093024) - quetiapinfumarat (ph.eur.) - filmtablette - quetiapinfumarat (ph.eur.) (30625) 345,36 milligramm
quetiapin accord 200 mg filmtabletten
accord healthcare limited (8093024) - quetiapinfumarat (ph.eur.) - filmtablette - quetiapinfumarat (ph.eur.) (30625) 230,24 milligramm
quetiapin accord 25 mg filmtabletten
accord healthcare limited (8093024) - quetiapinfumarat (ph.eur.) - filmtablette - quetiapinfumarat (ph.eur.) (30625) 28,78 milligramm
quetiapin accord 150 mg filmtabletten
accord healthcare limited (8093024) - quetiapinfumarat (ph.eur.) - filmtablette - quetiapinfumarat (ph.eur.) (30625) 172,68 milligramm